Squarepoint’s Collegium Pharmaceutical COLL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.73M | Buy |
47,897
+26,589
| +125% | +$909K | ﹤0.01% | 2459 |
|
|
2026
Q1 | $705K | Sell |
21,308
-8,800
| -29% | -$373K | ﹤0.01% | 3064 |
|
|
2025
Q4 | $1.39M | Buy |
30,108
+19,532
| +185% | +$817K | ﹤0.01% | 2335 |
|
|
2025
Q3 | $370K | Sell |
10,576
-1,526
| -13% | -$53K | ﹤0.01% | 3500 |
|
|
2025
Q2 | $358K | Sell |
12,102
-23,003
| -66% | -$656K | ﹤0.01% | 3555 |
|
|
2025
Q1 | $1.05M | Sell |
35,105
-4,450
| -11% | -$136K | ﹤0.01% | 2618 |
|
|
2024
Q4 | $1.13M | Sell |
39,555
-82,918
| -68% | -$2.74M | ﹤0.01% | 2946 |
|
|
2024
Q3 | $4.73M | Buy |
122,473
+12,135
| +11% | +$433K | 0.01% | 1454 |
|
|
2024
Q2 | $3.55M | Buy |
110,338
+72,874
| +195% | +$2.53M | 0.01% | 1614 |
|
|
2024
Q1 | $1.45M | Sell |
37,464
-1,272
| -3% | -$44.5K | ﹤0.01% | 2320 |
|
|
2023
Q4 | $1.19M | Sell |
38,736
-13,627
| -26% | -$341K | ﹤0.01% | 2402 |
|
|
2023
Q3 | $1.17M | Buy |
52,363
+27,076
| +107% | +$618K | ﹤0.01% | 2209 |
|
|
2023
Q2 | $543K | Buy |
+25,287
| New | +$574K | ﹤0.01% | 2572 |
|
|
2022
Q2 | – | Sell |
-36,997
| Closed | -$753K | – | 2944 |
|
|
2022
Q1 | $753K | Buy |
36,997
+22,108
| +148% | +$418K | ﹤0.01% | 1755 |
|
|
2021
Q4 | $278K | Buy |
+14,889
| New | +$290K | ﹤0.01% | 2490 |
|
|
2021
Q3 | – | Sell |
-29,096
| Closed | -$688K | – | 2985 |
|
|
2021
Q2 | $688K | Buy |
29,096
+18,147
| +166% | +$419K | ﹤0.01% | 1913 |
|
|
2021
Q1 | $259K | Buy |
+10,949
| New | +$260K | ﹤0.01% | 2521 |
|
|
2020
Q4 | – | Sell |
-10,944
| Closed | -$228K | – | 2967 |
|
|
2020
Q3 | $228K | Sell |
10,944
-7,317
| -40% | -$132K | ﹤0.01% | 2003 |
|
|
2020
Q2 | $320K | Sell |
18,261
-15,537
| -46% | -$304K | 0.01% | 1565 |
|
|
2020
Q1 | $552K | Sell |
33,798
-34,542
| -51% | -$713K | 0.01% | 982 |
|
|
2019
Q4 | $1.41M | Sell |
68,340
-13,977
| -17% | -$233K | 0.01% | 1118 |
|
|
2019
Q3 | $945K | Buy |
82,317
+4,843
| +6% | +$55.3K | 0.01% | 1276 |
|
|
2019
Q2 | $1.02M | Buy |
77,474
+27,613
| +55% | +$369K | 0.01% | 1254 |
|
|
2019
Q1 | $755K | Buy |
49,861
+31,725
| +175% | +$508K | 0.01% | 1246 |
|
|
2018
Q4 | $311K | Sell |
18,136
-33,764
| -65% | -$578K | ﹤0.01% | 1490 |
|
|
2018
Q3 | $765K | Buy |
51,900
+18,100
| +54% | +$321K | 0.01% | 1112 |
|
|
2018
Q2 | $806K | Buy |
33,800
+17,092
| +102% | +$420K | 0.01% | 975 |
|
|
2018
Q1 | $427K | Sell |
16,708
-9,387
| -36% | -$224K | 0.01% | 1151 |
|
|
2017
Q4 | $482K | Buy |
+26,095
| New | +$374K | 0.01% | 1232 |
|
Other funds holding COLL
JT
EAM
Squarepoint's COLL Position: Q2 2026 in Review
Squarepoint increased its Collegium Pharmaceutical (COLL) stake by 125% in Q2 2026, buying an estimated $909K and bringing the position to 47,897 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2459.
Squarepoint first reported a position in COLL in Q4 2017 and has held it in 29 quarters since. The position peaked at $4.73M in Q3 2024. 280 funds tracked by Wall St. Rank hold COLL as of Q2 2026.
- Squarepoint held 47,897 shares of Collegium Pharmaceutical worth $1.73M as of Q2 2026.
- Squarepoint bought 26,589 Collegium Pharmaceutical shares in Q2 2026, an estimated $909K.
- Collegium Pharmaceutical made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #2459 holding.
- Squarepoint first reported a position in Collegium Pharmaceutical in Q4 2017 and has held it in 29 quarters since.
- Squarepoint's Collegium Pharmaceutical position peaked at $4.73M in Q3 2024.
- 280 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.